{
 "checked": "2026-10-24",
 "drugsfda_active_ingredient_search": {
  "endpoint": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22NAME%22",
  "results": {
   "BPC-157": "none",
   "BREMELANOTIDE": [
    "NDA210557 VYLEESI (AUTOINJECTOR) (Prescription)"
   ],
   "CATHELICIDIN": "none",
   "CJC-1295": "none",
   "DIHEXA": "none",
   "ELAMIPRETIDE": [
    "NDA215244 FORZINITY (Prescription)"
   ],
   "EMIDELTIDE": "none",
   "EPITALON": "none",
   "GHK": "none",
   "GLUTATHIONE": [
    "NDA018469 BSS PLUS (Prescription)",
    "NDA020079 METHOTREXATE SODIUM (Discontinued)"
   ],
   "IPAMORELIN": "none",
   "KPV": "none",
   "MECHANO GROWTH": "none",
   "MELANOTAN": "none",
   "MOTS-C": "none",
   "NICOTINAMIDE ADENINE DINUCLEOTIDE": "none",
   "SELANK": "none",
   "SEMAX": "none",
   "SERMORELIN": [
    "NDA019863 GEREF (Discontinued)",
    "NDA020443 GEREF (Discontinued)"
   ],
   "TESAMORELIN": [
    "BLA022505 EGRIFTA (Prescription)"
   ],
   "THYMALFASIN": "none",
   "THYMOSIN ALPHA": "none",
   "THYMOSIN BETA": "none"
  }
 },
 "ecfr_216_23_list": [
  "Brilliant Blue G",
  "Cantharidin (topical)",
  "Diphenylcyclopropenone (topical)",
  "N-acetyl-D-glucosamine (topical)",
  "Squaric acid dibutyl ester (topical)",
  "Thymol iodide (topical)"
 ],
 "category_1_relevant": [
  "Glutathione",
  "Nicotinamide Adenine Dinucleotide (NAD)",
  "GHK-Cu (except for injectable routes of administration), added back after May 5, 2026 clarification"
 ],
 "category_3_relevant": [
  "Mechano growth factor (MGF)"
 ],
 "category_2_active_503A_peptides_not_covered": [
  "Ibutamoren Mesylate",
  "Kisspeptin-10"
 ],
 "category_2_nominated_but_withdrawn_covered": [
  "BPC-157",
  "Cathelicidin LL-37",
  "CJC-1295",
  "Dihexa acetate",
  "Emideltide (DSIP)",
  "Epitalon",
  "GHK-Cu (injectable routes)",
  "Ipamorelin acetate",
  "KPV",
  "Melanotan II",
  "MOTs-C",
  "PEG-MGF",
  "Selank acetate",
  "Semax",
  "TB-500",
  "Thymosin-alpha 1"
 ],
 "pcac_july_2026": {
  "fda_staff": "against all seven (briefing conclusions: a balancing of the criteria weighs against inclusion)",
  "reported_tallies_yes_no_abstain": {
   "BPC-157": "8-6-1",
   "KPV": "8-6-1",
   "TB-500": "8-6-1",
   "Semax": "8-5-1",
   "Epitalon": "7-4-1 or 7-5-1",
   "MOTS-c": "7-5-2",
   "Emideltide (DSIP)": "6-7-1"
  },
  "fda_minutes_posted": false
 },
 "pcac_next": {
  "deadline": "before the end of February 2027",
  "agenda": [
   "Cathelicidin (LL-37)",
   "GHK-Cu",
   "Dihexa acetate",
   "Melanotan II",
   "PEG-MGF"
  ],
  "date_set": false
 },
 "pcac_2024_minutes": {
  "Ipamorelin (Oct 29, 2024)": {
   "free base": "0/12/1",
   "acetate": "0/12/1"
  },
  "CJC-1295 (Dec 4, 2024)": {
   "free base": "0/13/0",
   "acetate": "1/12/0",
   "DAC free base": "0/13/0",
   "DAC acetate": "0/13/0",
   "DAC TFA": "0/13/0"
  },
  "Thymosin alpha-1 (Dec 4, 2024)": {
   "free base": "4/17/0",
   "acetate": "4/17/0"
  },
  "AOD-9604 (Dec 4, 2024)": "0/12"
 },
 "oira_rin_0910_zd94": {
  "received": "2026-10-14",
  "status": "Pending EO 12866 review",
  "text_public": false
 },
 "chart_groups": [
  {
   "label": "Committee voted to add in July 2026; FDA staff recommended against (final decision pending)",
   "color": "amb",
   "members": [
    "BPC-157",
    "KPV",
    "TB-500",
    "MOTS-c",
    "Semax",
    "Epitalon"
   ]
  },
  {
   "label": "Committee voted against in July 2026; FDA staff also against",
   "color": "red",
   "members": [
    "DSIP (emideltide)"
   ]
  },
  {
   "label": "Committee voted against in 2024, as FDA proposed",
   "color": "red",
   "members": [
    "CJC-1295",
    "Ipamorelin",
    "Thymosin alpha-1"
   ]
  },
  {
   "label": "On the next committee agenda, due before the end of February 2027",
   "color": "amb",
   "members": [
    "GHK-Cu",
    "LL-37",
    "Dihexa",
    "Melanotan II",
    "PEG-MGF"
   ]
  },
  {
   "label": "Nomination withdrawn, on FDA’s safety-risk page, no meeting announced",
   "color": "gry",
   "members": [
    "Selank"
   ]
  },
  {
   "label": "FDA category 1, “under evaluation”",
   "color": "col",
   "members": [
    "Glutathione",
    "NAD+ (not a peptide)",
    "GHK-Cu, non-injectable only"
   ]
  },
  {
   "label": "Ingredient of an FDA-approved drug",
   "color": "grn",
   "members": [
    "PT-141 (Vyleesi)",
    "SS-31 (Forzinity)",
    "Tesamorelin (Egrifta)",
    "Sermorelin (Geref, discontinued)"
   ]
  }
 ]
}